A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study)

European Journal of Surgical Oncology

Volumn 36, Issue 6, 2010, Pages 546-551

  Yoshikawa, T ^a   Omura, K ^b   Kobayashi, O ^a   Nashimoto, A ^c   Takabayashi, A ^d   Yamada, T ^e   Yamaue, H ^f   Fujii, M ^g   Yamaguchi, T ^h   Nakajima, T ⁱ  

^a KANAGAWA CANCER CENTER   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c Department of Surgery   (Japan)

^d Kitano Hospital   (Japan)

^e ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^f WAKAYAMA UNIVERSITY   (Japan)

^g NIHON UNIVERSITY   (Japan)

^h CANCER INSTITUTE HOSPITAL   (Japan)

ⁱ Japan Clinical Cancer Research Organization   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Phase II; Surgery

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN;

ABDOMINAL ABSCESS; ADULT; AGED; ANASTOMOSIS LEAKAGE; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; GASTRECTOMY; HUMAN; KIDNEY DISEASE; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PANCREAS FISTULA; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; SEROSA; SIDE EFFECT; SKIN PIGMENTATION; STOMACH CANCER; SURGICAL MORTALITY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WOUND INFECTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PREOPERATIVE CARE; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 77953089546     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.04.011     Document Type: Article

References (22)

1. Torrado J., Santiseban A., and Ruiz-Ederra J. Genetic susceptibility to gastric cancer. Hepato-Gastroenterology 48 (2001) 1544-1547
2. Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol 21 (2003) 274-275
3. Maeta M., Yamashiro H., Saito H., et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery 125 (1999) 325-331
4. Díaz de Liaño A., Yarnoz C., Aguilar R., et al. Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer 11 (2008) 96-102
5. Nakajima T., and Yamaguchi T. Gastric cancer database 1946-2004 in Cancer Institute Hospital (2006), Kanehara & Co, Tokyo
6. Ohtsu A., Yoshida S., and Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 24 (2006) 2188-2196
7. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357 (2007) 1810-1820
8. Ott K., Lordick F., Hermann K., et al. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer 11 (2008) 1-9
9. Koizumi W., Tanabe S., Saigenji K., et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89 (2003) 2207-2212
10. Koizumi W., Narahara H., Hara T., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9 (2008) 215-221
11. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24 (2006) 4991-4997
12. Sano T., Sasako M., Yamamoto S., et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy - Japan Clinical Oncology Group study 9501. J Clin Oncol 22 (2004) 2767-2773
13. Yoshikawa T., Sasako M., Yamamoto S., et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 96 (2009) 1015-1022
14. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1 (1998) 10-24
15. Sasako M., Sano T., Yamamoto S., et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359 (2008) 453-462
16. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
17. National Cancer Institute. Common Toxicity Criteria version 2.0 (CTC) (1999). http://ctep.cancer.gov/reporting/CTC-3.html Available from:
18. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
19. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
20. Baba H., Yamamoto M., Endo K., et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer 6 (2003) 45-49
21. Satoh S., Hasegawa S., Ozaki N., et al. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using S-1/CDDP combination. Gastric Cancer 9 (2006) 129-135
22. Nakagawa S., Nashimoto A., and Yabusaki H. Role of staging laparoscopy with peritoneal lavage cytology in the treatment of locally advanced gastric cancer. Gastric Cancer 10 (2007) 29-34